Glaxosmithkline Biologicals Sa

Smithkline Beecham Biologicals S.a.

Other

Max-Planck-Gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Corixa Corporation

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Infectious Disease Research Institute

Yves Lobet

Steven G Reed

Jan Poolman

Markus M Simon

Michael D Kramer

Ulrich E Schaible

Reinhard Wallich

Camille Locht

Yasir A Skeiky

Mark R Alderson

Peter Probst

Ajay Bhatia

Philippe Denoel

Rhea N Coler

Joelle Thonnard

Martine Marchand

Pascal Mettens

Pierre Voet

Jean-Francois Lucien Maisonneuve

Guy Dequesne

Christiane Feron

Brenda Maisonneuve

Florence Bernadette Nozay

Georges Thiry

Francois-Xavier Jacques Berthet

Wilfried L Dalemans

Craig Antony Joseph Laferrière

Wilfred L J Dalemans

The present invention is directed to methods of preventing reactivation of active and latentinfections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against ainfection. The methods also provide for shortening the time course of a chemotherapeutic regimen against ainfection.

[object Object]

The present invention relates to compositions comprising proteins or polynucleotides ofsp., in particular combinations of proteins or polynucleotides encoding them, and methods for the use of the proteins or polynucleotides in the treatment, prevention and diagnosis ofinfection.

Vaccines against chlamydial infection

The invention related to novel Borrelia, and OspA antigens derived therefrom. These antigens show little homology with know OspA's and are therefore useful as vaccine and diagnostic reagents. Multicomponent vaccines based on OspA's from different Borrelia groups are also disclosed.

Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines

Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and

The Bordetella pertussis toxin is genetically modified to express a toxin protein which is deficient in target-cell receptor binding and is used in a vaccine for protection against whooping cough.

Vaccine

The invention relates to novet Borrelia, and OspA antigens derived therefrom. These antigens show little homology with known OspA's and are therefore useful as vaccine and diagnostic reagents. Multicomponent vaccines based on OspA's from different Borrelia groups are also disclosed.

Growing community of inventors

Rixensart, Belgium

Yves Lobet